NDAORALTABLET
Approved
Nov 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
AVANDARYL (glimepiride; rosiglitazone maleate) by Teva is cells. Approved for type 2 diabetes mellitus ( ), type 1 diabetes mellitus, type 2 diabetes mellitus. First approved in 2005.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVANDARYL is a fixed-dose combination oral tablet containing glimepiride (a sulfonylurea) and rosiglitazone maleate (a thiazolidinedione) approved for type 2 diabetes mellitus. It works through dual mechanisms: glimepiride stimulates insulin release from pancreatic beta cells, while rosiglitazone enhances insulin sensitivity in peripheral tissues. This combination addresses both insulin secretion and insulin resistance.
LOE Approaching
Product lifecycle is approaching loss of exclusivity, signaling diminished investment in brand teams and likely consolidation or deprioritization of commercial resources.
Mechanism of Action
cells. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.
Indications (3)
Worked on AVANDARYL at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.